Management of anterior chamber dislocation of a dexamethasone intravitreal implant: A case report

被引:0
|
作者
Pacella F. [1 ]
Agostinelli E. [2 ]
Carlesimo S.C. [1 ]
Nebbioso M. [1 ]
Secondi R. [1 ]
Forastiere M. [1 ]
Pacella E. [1 ]
机构
[1] Department of Sense Organs, Faculty of Medicine and Dentistry, Sapienza University of Rome, Viale del Policlinico, Rome
[2] Department of Biochemical Sciences, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome
关键词
Case report; Cystoid macular edema; Intravitreal dexamethasone implant; Ozurdex; Ozurdex dislocation;
D O I
10.1186/s13256-016-1077-2
中图分类号
学科分类号
摘要
Background: Ozurdex is a 700 mcg dexamethasone intravitreal implant, approved for the management of macular edema secondary to retinal vein occlusion, and other related pathoglogiesAnterior chamber dislocation of Ozurdex represents an uncommon complication of the intravitreal injection, which can be managed by repositioning the implant into the vitreous cavity. We describe the case of a successful repositioning of an Ozurdex implant by mobilization and subsequent balanced saline solution injection in the anterior chamber. Case presentation: An 83-year-old white woman presented to our Emergency Unit complaining of pain and vision loss in herright eye lasting a week. Her anamnesis revealed a history of persistent cystoid macular edema after phacoemulsification with scleral-fixated posterior chamber intraocular lens implantation, recently treated with an intravitreal Ozurdex implant. She also took a long-distance flight 2 days after the injection. An anterior segment examination showed corneal edema and the rod implant adherent to corneal endothelium. To avoid corneal decompensation, we opted for a implant repositioning. Under topical anesthesia, a 30-gauge needle was introduced through a limbar incisionto mobilize the dislocated rod. Balanced saline solution was injected, with a successful repositioning of the implant into the vitreous cavity. Topical 5 % hypertonic saline solution and 0.2 % betamethasone associated with 0.5 % chloramphenicol drops were administered four times a day. To prevent redislocation of the Ozurdex implant, she was instructed to avoid prone position, any kind of physical effort, and not to undertake long-distance flights during the first postoperative week. One week after surgery, an anterior segment examination showed an improvement of corneal edema. Funduscopy showed that the Ozurdex implant was settled into the vitreous cavity. Conclusions: Anterior chamber dislocation of Ozurdex from the vitreous cavity is rare. In our patient, in addition to the posterior capsule tearing, the long-distance flight could have contributed to implant dislocation. Repositioning of the implant is necessary to avoid endothelial decompensation. It can be carried out by using saline balanced solution with the same efficacy as other surgical procedures reported in the literature. A possible disadvantage of this procedure could be implant migration. © 2016 The Author(s).
引用
收藏
相关论文
共 50 条
  • [41] The Efficacy and Safety of Intravitreal Dexamethasone Implant as Anti-inflammatory Monotherapy in the Management of Tuberculosis-associated Intermediate Uveitis
    Baharani, Abhilasha
    Reddy P., Raja Rami
    Patil, Pritam Manohar
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2023, 31 (08) : 1594 - 1602
  • [42] The Role of Dexamethasone Implant in the Management of Tubercular Uveitis
    Agarwal, Aniruddha
    Handa, Sabia
    Aggarwal, Kanika
    Sharma, Mansi
    Singh, Ramandeep
    Sharma, Aman
    Agrawal, Rupesh
    Sharma, Kusum
    Gupta, Vishali
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2018, 26 (06) : 884 - 892
  • [43] Scleral fixation of dexamethasone intravitreal implant (OZURDEX®) in a case of angle-supported lens implantation
    Carlos Mateo
    Micol Alkabes
    Anniken Burés-Jelstrup
    International Ophthalmology, 2014, 34 : 661 - 665
  • [44] Dexamethasone Intravitreal Implant for Chronic Diabetic Macular Edema Resistant to Intravitreal Bevacizumab Treatment
    Totan, Yuksel
    Guler, Emre
    Guragac, Fatma Betul
    CURRENT EYE RESEARCH, 2016, 41 (01) : 107 - 113
  • [45] IMPACT OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) ON MACULAR MORPHOLOGY AND FUNCTION
    Querques, Giuseppe
    Lattanzio, Rosangela
    Querques, Lea
    Triolo, Giacinto
    Cascavilla, Maria L.
    Cavallero, Edoardo
    Del Turco, Claudia
    Casalino, Giuseppe
    Bandello, Francesco
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (02): : 330 - 341
  • [46] Intravitreal dexamethasone implant for macular edema following uncomplicated phacoemulsification
    Furino, Claudio
    Boscia, Francesco
    Recchimurzo, Nicola
    Sborgia, Carlo
    Alessi, Giovanni
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2014, 24 (03) : 387 - 391
  • [47] Intravitreal dexamethasone implant for acute exudative polymorphous vitelliform maculopathy
    Scupola, Andrea
    Abed, Edoardo
    Sammarco, Maria Grazia
    Traina, Salvatore
    Villano, Antonio
    Grimaldi, Gabriela
    Blasi, Maria Antonietta
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2014, 24 (05) : 803 - 807
  • [48] Long-Term Intravitreal Dexamethasone Implant Outcomes in Uveitis
    Alba-Linero, Carmen
    Sala-Puigdollers, Anna
    Romero, Barbara
    Llorenc, Victor
    Adan, Alfredo
    Zarranz-Ventura, Javier
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2020, 28 (02) : 228 - 237
  • [49] Intravitreal Dexamethasone Implant in Patients with Persistent Diabetic Macular Edema
    Zucchiatti, Ilaria
    Lattanzio, Rosangela
    Querques, Giuseppe
    Querques, Lea
    Del Turco, Claudia
    Cascavilla, Maria Lucia
    Bandello, Francesco
    OPHTHALMOLOGICA, 2012, 228 (02) : 117 - 122
  • [50] Intravitreal slow-releasing dexamethasone implant for idiopathic neuroretinitis
    Cekic, Osman
    Gulkas, Samet
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2022, 32 (01) : NP226 - NP229